Kura Oncology, Inc. — Form 10-Q Summary
Business Context and Reporting Period
Kura Oncology is a clinical-stage biopharmaceutical company developing precision medicines for genetically defined cancers. The filing covers the three months ended March 31, 2020, with unaudited financial statements prepared under U.S. GAAP. The company had no approved products and generated no product revenue.
- Lead program: tipifarnib, including the AIM-HN registration-directed trial in HRAS-mutant head and neck squamous cell carcinoma.
- Other principal program: KO-539, a menin-KMT2A inhibitor in a Phase 1/2A trial for relapsed or refractory acute myeloid leukemia.
- Common shares outstanding at April 30, 2020: 45.4 million.
Financial Results and Key Metrics
| Metric | Q1 2020 | Q1 2019 | Change |
|---|---|---|---|
| Research and development expense | $12.6 million | $10.4 million | +$2.2 million |
| General and administrative expense | $7.6 million | $4.6 million | +$3.1 million |
| Total operating expenses | $20.2 million | $15.0 million | +$5.2 million |
| Other income, net | $1.0 million | $1.0 million | Approximately flat |
| Net loss | $19.2 million | $13.9 million | +$5.3 million loss |
| Net loss per share | $0.42 | $0.37 | Higher loss per share |
| Net cash used in operating activities | $19.8 million | $14.3 million | +$5.6 million use |
- Revenue and margins: no product revenue was reported; gross margin and operating margin are not meaningful for this clinical-stage company. The filing does not provide a clear revenue-based margin measure.
- Cash and liquidity: cash, cash equivalents and short-term investments totaled $216.9 million at March 31, 2020, including $33.8 million of cash and cash equivalents and $183.1 million of short-term investments.
- Total assets were $226.5 million and stockholders’ equity was $203.2 million at March 31, 2020.
- Debt: $7.5 million was outstanding under the Silicon Valley Bank term loan facility, consisting of $1.0 million current debt and $6.5 million long-term debt. The company could draw up to an additional $12.5 million through November 30, 2020.
- Interest rate on the term loans was 5.50% at March 31, 2020; principal payments were scheduled to begin December 1, 2020, with maturity on May 1, 2023.
- Share-based compensation expense was $3.2 million, compared with $2.3 million in Q1 2019.
- Accumulated deficit was $232.1 million at March 31, 2020.
Material Changes Versus the Prior Comparable Period
- Research and development expense increased 21%, primarily due to higher personnel and other costs, increased KO-539 activity following initiation of its Phase 1/2A trial, and continued tipifarnib development.
- General and administrative expense increased 67%, driven by higher pre-commercial planning, recruiting, personnel and share-based compensation costs.
- Net loss increased 38% and operating cash burn increased 39% year over year.
- Tipifarnib-related R&D costs increased to $6.2 million from $5.9 million; KO-539-related costs increased to $0.9 million from $0.4 million; KO-947-related costs declined to $0.8 million from $1.0 million.
- Cash, cash equivalents and restricted cash increased to $34.0 million from $26.1 million at year-end, primarily because investment maturities and sales exceeded purchases despite operating cash burn.
- The company recorded approximately $2.2 million of operating lease right-of-use assets and lease liabilities associated with new San Diego office facilities.
Guidance, Outlook, Commentary and Risks
- Management stated that existing cash, cash equivalents and short-term investments were expected to fund operating expenses and capital requirements into 2022, based on current plans. This is not a guarantee and depends on clinical, regulatory and financing developments.
- COVID-19 caused slower patient screening and enrollment, site restrictions and potential disruptions involving contract research organizations, manufacturers and clinical sites. Management expected delays to AIM-HN timelines and could not reasonably forecast when the trial would be fully enrolled.
- On May 4, 2020, the company announced a pipeline prioritization: suspension of a planned tipifarnib registration-directed study in T-cell lymphoma, suspension of a planned tipifarnib Phase 2 pancreatic cancer trial and termination of the KO-947 ERK inhibitor program.
- The company intended to amend AIM-HN to enroll patients with any HRAS mutation, potentially increasing enrollment requirements while retaining objective response rate in patients with high HRAS mutant variant allele frequency as the primary outcome measure.
- The company had a $75.0 million at-the-market equity facility but had not sold shares under it as of the filing. Additional financing is expected to be required, and future equity or debt financing could be dilutive or unavailable on acceptable terms.
- Tipifarnib remains dependent on successful clinical results, regulatory approval and an approved companion diagnostic for HRAS-mutant HNSCC. Fast Track designation does not assure approval or materially faster development.
- Additional contingent obligations include up to approximately $80.0 million of milestone payments under an in-license agreement, plus potential sales royalties, if specified milestones are achieved.
- The filing disclosed no material legal proceedings and no off-balance-sheet arrangements. Management concluded that disclosure controls and procedures were effective as of March 31, 2020.
Most Important Facts for Investors to Verify
- Whether COVID-19-related enrollment and site disruptions materially changed AIM-HN timing, cost or statistical design.
- Progress, safety, enrollment and efficacy data for AIM-HN and KOMET-001, including the effect of broader HRAS enrollment criteria.
- Actual cash burn and whether the stated liquidity runway into 2022 remains valid after pipeline changes and operating adjustments.
- Whether the additional $12.5 million term-loan draw was made and whether the company used its ATM facility or other financing sources after March 31, 2020.
- Regulatory and development status of tipifarnib’s companion diagnostic and the prospects for any accelerated approval pathway.
- Financial effects of suspending or terminating the T-cell lymphoma, pancreatic cancer and KO-947 programs.
- Potential dilution from future equity issuance, outstanding options, warrants and the effective resale registration statement covering 13.9 million shares.